Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus COGNEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus COGNEX.
ARICEPT vs COGNEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversible acetylcholinesterase inhibitor, increases acetylcholine concentration at cholinergic synapses.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Initial dose 10 mg orally 4 times daily (40 mg/day); may increase by 10 mg/day every 6 weeks up to 160 mg/day (40 mg 4 times daily).
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life is approximately 7-10 hours; clinical context: allows twice-daily dosing in most patients.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Primarily renal (approximately 40-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor